

Zydus
dedicated to life

Cadila
Healthcare Limited

Regd. Office :

'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015, India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 8337

December 11, 2013

Bombay Stock Exchange Limited

1st Floor, P.J. Towers
Dalal Street
MUMBAI – 400 001

Attention: Mr. Sanjay Golecha
Mr. Gopalkrishnan

Fax No. 022 – 22722039 / 3121

National Stock Exchange of India Ltd.

Exchange Plaza, 5th Floor,
Plot No. C/1, G Block
Bandra- Kurla Complex
Bandra – (East)
Mumbai – 400 051

Attention: Famroze Pochara
Asst. Vice President

Fax No. 022 – 26598237/38

Ahmedabad Stock Exchange Limited

Kamdheni Complex
Opp. Sahajanand College
Panjra Pole,
Ahmedabad – 380 015

Fax No. 079 - 26308877

Re.: Press Release

Dear Sir / Madam


We enclose herewith a copy of press release dated December 11, 2013 in the matter of entering into in principal agreement with Warner Chilcoat Company LLP by the Company and Zydus Pharmaceuticals (USA) Inc., to settle all outstanding patent litigation related to Asacol ® HD (mesalamine) delayed-release tablets to be released in the newspapers which gives the full details of the same.

Please bring the aforesaid news to the notice of the members of the exchange and the investors at large.

Thanking you,

Yours faithfully,

FOR CADILA HEALTHCARE LIMITED



UPEN H. SHAH
COMPANY SECRETARY

Encl.: As above.



Release

Press Release

Release

Press Release

For Immediate Release

December 11, 2013

Cadila Healthcare Limited, a global pharmaceuticals company, and Zydus Pharmaceuticals (USA), Inc., a leading generic pharmaceutical company in the United States, today announced that they have entered into an agreement in principle with Warner Chilcott Company LLC to settle all outstanding patent litigation related to Asacol® HD (mesalamine) delayed-release tablets. The agreement remains subject to preparation and execution of definitive documentation.

Under the terms of the agreement in principle, Warner Chilcott Company will grant Cadila and Zydus a royalty-bearing license to market a generic version of Asacol® HD beginning on November 15, 2015 or earlier under certain circumstances, following receipt by Zydus of final approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for generic Asacol® HD.

Alternatively, if Zydus does not receive FDA approval of its generic Asacol® HD by July 1, 2016, Zydus will be permitted to launch an authorized generic version of Asacol® HD beginning on July 1, 2016. Other terms of the settlement were not disclosed.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 15,000 people worldwide and is dedicated to creating healthier communities globally. Zydus Cadila is the only Indian pharma company to launch its own patented NCE - Lipaglyn™, the world's first drug to be approved for the treatment of diabetic dyslipidemia. It aims to be a leading global healthcare provider with a robust product pipeline, achieve sales of over \$3 billion by 2015 and be a research-based pharmaceutical company by 2020.